Women's Health

Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.

Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.

A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.

Women with endometriosis have a 46% higher type 2 diabetes risk, highest among premenopausal, non-obese women, study finds.

Endometriosis was found to nearly double absenteeism and work-ability impairment, according to one study.

A new iPSC-derived platform from patients with endometriosis captures the disease's molecular and hormonal features in a human context.

New Harris Poll data show mental health, access, and postpartum care gaps persist for US mothers, with Black and Hispanic women hit hardest.

A poll finds awareness of the mifepristone abortion pill is rising, but safety doubts and legal battles persist.

Nearly 1 in 3 women aged 21 to 29 and 1 in 7 aged 30 to 65 had never been screened for cervical cancer by 2023.

A new $20 billion national strategy targets long-standing gaps in women's health research, care, and funding.

The FDA approved Viatris' Gwyn Lo, a once-weekly low-dose estrogen (20 mcg) contraceptive patch, based on phase 3 LUMINOUS data showing a Pearl Index of 4.14 pregnancies per 100 woman-years and strong adhesion (98.7% intact). It's approved for women with BMI under 30; common side effects included application-site irritation and intercycle bleeding. Available later in 2026.

Women with PMOS had more than 4 times the adjusted ASCVD risk of matched peers, and traditional risk factors explained only about a third of the gap.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

A new study finds Texas's abortion ban raised the likelihood of poor maternal mental health by 2.5 points—and 7 points for mothers on Medicaid.

I-SPY 2.2 of rilvegostomig plus trastuzumab deruxtecan in breast cancer treatment cut chemo use while exposing access issues and disparities.

Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

Nancy Lin, MD, explains how an AI model compares with genomic classifiers in HR+/HER2- early breast cancer, with implications for cost and access.

Diet quality, carbohydrate quantity, and macronutrient composition may influence gestational glycemia, with consequences well into the postpartum period.

Chronic inflammation, hormonal imbalance, and surgical management all deplete ovarian reserve in endometriosis patients, a new systematic review finds.

Study finds endometriosis severity plateaus after 30, but surgery risk and complexity climb in older women as fibrosis and adhesions build.

The scoping review shows menopause and multiple sclerosis (MS) shift from fewer relapses to higher symptom burden, highlighting care gaps for older women with MS.

Endometriosis is often mistaken for IBS, fibroids, UTIs, PID, and ovarian cysts, potentially delaying diagnosis, treatment, and fertility care for years.

The FDA approves Datroway for first-line metastatic triple-negative breast cancer in immunotherapy-ineligible patients.

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk after, reshaping care.